Cadila Healthcare is currently trading at Rs. 347.25, up by 2.90 points or 0.84% from its previous closing of Rs. 344.35 on the BSE.
The scrip opened at Rs. 346.50 and has touched a high and low of Rs. 350.50 and Rs. 343.00 respectively. So far 164974 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 378.00 on 09-Apr-2020 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 352.65 and Rs. 321.80 respectively. The current market cap of the company is Rs. 35406.14 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.45% and 7.67% respectively.
Zydus Cadila has supplied first batch of 30,000 COVID KAVACH ELISA Tests witch manufactured by Zydus Diagnostics, a unit of company, to Indian Council of Medical Research (ICMR), free of cost. These test kits have been manufactured in technology transfer with ICMR-NIV of Pune for surveillance purposes. The test named as ‘COVID KAVACH ELISA’ have been manufactured in just four days of receiving all necessary materials from ICMR - NIV, Pune.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.